Cargando…
Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor
Although respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants and young children, attempts to develop an effective therapy have so far proved unsuccessful. Here we report the preclinical profiles of PC786, a potent nonnucleoside RSV L protein pol...
Autores principales: | Coates, Matthew, Brookes, Daniel, Kim, Young-In, Allen, Heather, Fordyce, Euan A. F., Meals, Elizabeth A., Colley, Thomas, Ciana, Claire-Lise, Parra, Guillaume F., Sherbukhin, Vladimir, Stockwell, Jennifer A., Thomas, Jennifer C., Hunt, S. Fraser, Anderson-Dring, Lauren, Onions, Stuart T., Cass, Lindsey, Murray, Peter J., Ito, Kazuhiro, Strong, Pete, DeVincenzo, John P., Rapeport, Garth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571287/ https://www.ncbi.nlm.nih.gov/pubmed/28652242 http://dx.doi.org/10.1128/AAC.00737-17 |
Ejemplares similares
-
Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study
por: DeVincenzo, John, et al.
Publicado: (2020) -
A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein
por: DeVincenzo, John, et al.
Publicado: (2020) -
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
por: Detalle, Laurent, et al.
Publicado: (2015) -
Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor
por: Wang, Li, et al.
Publicado: (2021) -
Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
por: Sake, Svenja M., et al.
Publicado: (2022)